This content is not available in your region

Teva's UK arm recalls some batches of Ranitidine - Medicines watchdog

Access to the comments Comments
Teva's UK arm recalls some batches of Ranitidine - Medicines watchdog
The logo of Teva Pharmaceutical Industries is seen during a news conference hold by its CEO, Kare Schultz, to discuss the company's 2019 outlooks in Tel Aviv, Israel February 19, 2019. REUTERS/Amir Cohen   -   Copyright  AMIR COHEN(Reuters)
Text size Aa Aa

(Reuters) – Teva Pharmaceutical’s <TEVA.TA> <TEVA.N> UK unit has recalled some batches of heartburn medicine Ranitidine, Britain’s medicines watchdog said on Thursday, making it the latest drugmaker to pull the product.

Teva, the world’s largest generic drugmaker, is recalling all unexpired stock of Ranitidine Effervescent Tablets in 150 micrograms and 300 micrograms dosages, the Medicines and Healthcare products Regulatory Agency (MHRA) said

Teva did not immediately respond to a request for comment.

Rantidine, a copycat of GlaxoSmithKline’s <GSK.L> Zantac, is being taken off the shelves after the U.S. Food and Drug Administration found “unacceptable” levels of a probable cancer-causing impurity in the drug.

GSK last week recalled Zantac in all markets.

U.S. and European health regulators said last month they were reviewing the safety of Ranitidine, after online pharmacy Valisure warned of possible contamination with an impurity called NDMA, which has carcinogenic potential.

Ranitidine is the latest drug in which cancer-causing impurities have been found. Regulators have been recalling some blood pressure and heart failure medicines since last year.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Bernard Orr)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.